Search

Kui Shin Voo

from Manvel, TX
Age ~63
Get Report
Also known as:
Kui S Voo, Kui K Voo, Kuishi S Voo, Kui S Vod, Kui S Von, N Voo
Phone and address:
3897 Shamrock Ln, Manvel, TX 77578
Related to:
Yolonda Danielle Wilderness, 46Sarah VooLay Sarah Sim Seow, 61
Connected to:
Brian K Voo, 39James Y Voo, 75Philip L Voo, 74Barry J Voodre, 58Bonnie Voodre, 64Arnold Voogd, 100Jennifer A Voogd, 41Susan Voogd, 79Richard J Vooght, 44Taylor J Vooght, 34

Kui Voo Phones & Addresses

  • 3897 Shamrock Ln, Manvel, TX 77578
  • 2207 Drake Falls Dr, Pearland, TX 77584 (713) 436-1713
  • Angleton, TX
  • Alvin, TX
  • Brazoria, TX
  • Indianapolis, IN
  • Raleigh, NC
  • 4135 S Webber Dr, Pearland, TX 77584

Resumes

Resumes

Kui Voo Photo 1

Research Scientist

View page
Location:
Pearland, TX
Industry:
Hospital & Health Care
Work:
Md Anderson Cancer Center
Research Scientist
Kui Voo Photo 2

Kui Voo

View page
Kui Voo Photo 3

Kui Voo

View page
Location:
United States

Business Records

Name / Title
Company / Classification
Phones & Addresses
Kui Shin Voo
Director
THE HUOQUAN LIVING SPRING CHURCH OF CHRIST
9917 Clodine Rd, Richmond, TX 77407
Kui S. Voo
Director
PEARLAND CHINESE FELLOWSHIP
Religious Organization
9504 Summer Sun Ln, Pearland, TX 77584

Publications

Us Patents

Anti-Ox40 Antibodies And Methods Of Using The Same

View page
US Patent:
20130280275, Oct 24, 2013
Filed:
Aug 23, 2011
Appl. No.:
13/818645
Inventors:
Yong-Jun Liu - Pearland TX, US
Kui Shin Voo - Pearland TX, US
Laura Bover - Pearland TX, US
Naoya Tsurushita - Palo Alto CA, US
J. Yun Tso - Menlo Park CA, US
Shankar Kumar - Pleasanton CA, US
Assignee:
BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM - Austin TX
International Classification:
C07K 16/28
US Classification:
4241731, 5303873, 536 2353, 435 696, 43525233, 43525421, 43525423, 435334, 5303896
Abstract:
Human antibodies, preferably recombinant human antibodies, both humanized and chimeric, which specifically bind to human OX40 are disclosed. Preferred antibodies have high affinity for OX40 receptor and activate the receptor in vitro and in vivo. The antibody can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, are useful for modulating receptor activity, e.g., in a human subject suffering from a disorder in which OX40 activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies are provided, and methods of synthesizing the recombinant human antibodies, are also provided.

Dual Specificity Antibodies To Pd-L1 And Pd-L2 And Methods Of Use Therefor

View page
US Patent:
20210214445, Jul 15, 2021
Filed:
Mar 15, 2019
Appl. No.:
17/040329
Inventors:
- Austin TX, US
Ashvin R. JAISWAL - Houston TX, US
Dongxing ZHA - Houston TX, US
Kui VOO - Houston TX, US
Carlo TONIATTI - Houston TX, US
Bianka PRINZ - Lebanon NH, US
Nga Rewa HOUSTON - Lebanon NH, US
Eric KRAULAND - Lebanon NH, US
Assignee:
Board of Regents, The University of Texas System - Austin TX
International Classification:
C07K 16/28
A61P 35/00
G01N 33/574
Abstract:
The present disclosure is directed to dual specificity antibodies which may bind to PD-L1 or PD-L2 and methods of using such antibodies to treat cancers, such as those that express or overexpress PD-L1 or PD-L2.

Anti-Ox40 Antibodies And Methods Of Using The Same

View page
US Patent:
20190100596, Apr 4, 2019
Filed:
Dec 13, 2018
Appl. No.:
16/219528
Inventors:
- Austin TX, US
Kui Shin VOO - Pearland TX, US
Laura BOVER - Pearland TX, US
Naoya TSURUSHITA - Palo Alto CA, US
J. Yun TSO - Menlo Park CA, US
Shankar KUMAR - Pleasanton CA, US
Assignee:
Board of Regents, The University of Texas System - Austin TX
International Classification:
C07K 16/28
A61K 39/00
Abstract:
Human antibodies, preferably recombinant human antibodies, both humanized and chimeric, which specifically bind to human OX40 are disclosed. Preferred antibodies have high affinity for OX40 receptor and activate the receptor in vitro and in vivo. The antibody can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, are useful for modulating receptor activity, e.g., in a human subject suffering from a disorder in which OX40 activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies are provided, and methods of synthesizing the recombinant human antibodies, are also provided.

Anti-Ox40 Antibodies And Methods Of Using The Same

View page
US Patent:
20170267773, Sep 21, 2017
Filed:
May 26, 2017
Appl. No.:
15/607386
Inventors:
- Austin TX, US
Kui Shin VOO - Pearland TX, US
Laura BOVER - Pearland TX, US
Naoya TSURUSHITA - Palo Alto CA, US
J. Yun TSO - Menlo Park CA, US
Shankar KUMAR - Pleasanton CA, US
Assignee:
Board of Regents, The University of Texas System - Austin TX
International Classification:
C07K 16/28
A61K 39/00
Abstract:
Human antibodies, preferably recombinant human antibodies, both humanized and chimeric, which specifically bind to human OX40 are disclosed. Preferred antibodies have high affinity for OX40 receptor and activate the receptor in vitro and in vivo. The antibody can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, are useful for modulating receptor activity, e.g., in a human subject suffering from a disorder in which OX40 activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies are provided, and methods of synthesizing the recombinant human antibodies, are also provided.

Anti-Ox40 Antibodies And Methods Of Using The Same

View page
US Patent:
20160068604, Mar 10, 2016
Filed:
Sep 15, 2015
Appl. No.:
14/854908
Inventors:
- Austin TX, US
Kui Shin VOO - Pearland TX, US
Laura BOVER - Pearland TX, US
Naoya TSURUSHITA - Palo Alto CA, US
J. Yun TSO - Menlo Park CA, US
Shankar KUMAR - Pleasanton CA, US
Assignee:
BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM - Austin TX
International Classification:
C07K 16/28
Abstract:
Human antibodies, preferably recombinant human antibodies, both humanized and chimeric, which specifically bind to human OX40 are disclosed. Preferred antibodies have high affinity for OX40 receptor and activate the receptor in vitro and in vivo. The antibody can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, are useful for modulating receptor activity, e.g., in a human subject suffering from a disorder in which OX40 activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies are provided, and methods of synthesizing the recombinant human antibodies, are also provided.

Anti-Ox40 Antibodies And Methods Of Using The Same

View page
US Patent:
20150315281, Nov 5, 2015
Filed:
Apr 13, 2015
Appl. No.:
14/684550
Inventors:
- Austin TX, US
Kui Shin VOO - Pearland TX, US
Laura BOVER - Pearland TX, US
Naoya TSURUSHITA - Palo Alto CA, US
J. Yun TSO - Menlo Park CA, US
Shankar KUMAR - Pleasanton CA, US
Assignee:
BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM - Austin TX
International Classification:
C07K 16/28
Abstract:
Human antibodies, preferably recombinant human antibodies, both humanized and chimeric, which specifically bind to human OX40 are disclosed. Preferred antibodies have high affinity for OX40 receptor and activate the receptor in vitro and in vivo. The antibody can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, are useful for modulating receptor activity, e.g., in a human subject suffering from a disorder in which OX40 activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies are provided, and methods of synthesizing the recombinant human antibodies, are also provided.

Anti-Ox40 Antibodies And Methods Of Using The Same

View page
US Patent:
20140308276, Oct 16, 2014
Filed:
Feb 9, 2012
Appl. No.:
14/240535
Inventors:
Yong-Jun Liu - Pearland TX, US
Kui Shin Voo - Pearland TX, US
Laura Bover - Pearland TX, US
Naoya Tsurushita - Palo Alto CA, US
J. Yun Tso - Menlo Park CA, US
Shankar Kumar - Pleasanton CA, US
Assignee:
BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM - Austin TX
International Classification:
C07K 16/28
US Classification:
4241331, 5303873, 536 2353, 435 696, 43525233, 43525421, 43525423, 435328, 4352351
Abstract:
Human antibodies, preferably recombinant human antibodies, both humanized and chimeric, which specifically bind to human OX40 are disclosed. Preferred antibodies have high affinity for OX40 receptor and activate the receptor in vitro and in vivo. The antibody can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, are useful for modulating receptor activity, e.g., in a human subject suffering from a disorder in which OX40 activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies are provided, and methods of synthesizing the recombinant human antibodies, are also provided.
Control profile
Kui Shin Voo from Manvel, TX, age ~63 Get Report